NEW INDICATIONS FOR DIRECT THROMBIN INHIBITORS IN THE CARDIOVASCULAR FIELD
The invention relates to new indications for direct thrombin inhibitors such as dabigatran etexilate in the cardiovascular field.
-
Page/Page column 17
(2008/06/13)
NEW INDICATIONS FOR DIRECT THROMBIN INHIBITORS
The invention relates to new indications for direct thrombin inhibitors such as dabigatran etexilate in the CNS and other fields.
-
Page/Page column 17
(2008/06/13)
New Paediatric Indications for Direct Thrombin Inhibitors
The invention relates to new paediatric indications for direct thrombin inhibitors such as dabigatran etexilate.
-
Page/Page column 7
(2008/06/13)
Physiologically acceptable salts of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
The invention relates to new, physiologically acceptable salts of the active substance ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate.
-
Page/Page column 3
(2008/06/13)
More Articles about upstream products of 1210812-51-3
Get Best Price for1210812-51-3ethyl 3-[(2-{[4-(amino-hexyloxycarbonylimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate tartaric acid salt